Remicade in the Treatment of Patients With Active Ankylosing Spondylitis
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The aim of the study was to evaluate the efficacy of infliximab (IFX) treatment, 5 mg/kg
every 6 weeks, in patients with active ankylosing spondylitis (AS) and to determine whether
IFX dose reduction and interval extension, 3 mg/kg every 8 weeks during the second year
sustained the treatment effect. The study was started in 2003 an finished in 2008.